SCHEMBL5503555

SCHEMBL5503555

COP(=O)(O)C(F)(F)c1ccccc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA5A P35218 1/20 0.42
CA9 Q16790 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 2/20 0.39
GAA P10253 1/20 0.39
PTPN1 P18031 4/20 0.38
PTPN2 P17706 1/20 0.38
NOTUM Q6P988 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
PDK1 Q15118 1/20 0.36
PDK2 Q15119 1/20 0.36
PDK3 Q15120 1/20 0.36
PDK4 Q16654 1/20 0.36
CDC14B O60729 1/20 0.35
CDC14A Q9UNH5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5508634 0.75 ALDH1A1 (0.42) CA1CA2CA5ACA9SMN1; SMN2
SCHEMBL5510355 0.74 ABCB11 (0.33) CA1CA2CA5ACA9SMN1; SMN2
SCHEMBL5506535 0.71 CA1 (0.41) CA1CA2CA5ACA9SMN1; SMN2
SCHEMBL29280609 0.68 NPSR1 (0.45) CA1CA2CA5ACA9SMN1; SMN2
SCHEMBL31612952 0.68 NPSR1 (0.45) CA1CA2CA5ACA9SMN1; SMN2
SCHEMBL548019 0.68 PLCG1 (0.49) CA1CA2CA5ACA9SMN1; SMN2
SCHEMBL3206788 0.67 CA1 (0.39) CA1CA2CA5ACA9SMN1; SMN2
SCHEMBL9129412 0.67 SRC (0.43) CA1CA2CA5ACA9SMN1; SMN2
SCHEMBL29559374 0.66 CA2 (0.50) CA1CA2CA5ACA9SMN1; SMN2
SCHEMBL4123029 0.66 CA2 (0.50) CA1CA2CA5ACA9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786421-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-05-23 EP claimed
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US claimed
WO-2006017124-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-02-16 WO claimed
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases PTPRO, PTPRG, PTPN1 CA1 2377/4885CA2 1730/4885CA5A 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.